<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04718168</url>
  </required_header>
  <id_info>
    <org_study_id>ENF 18-06</org_study_id>
    <nct_id>NCT04718168</nct_id>
  </id_info>
  <brief_title>GORE® ENFORM Biomaterial Product Study</brief_title>
  <acronym>ENF 18-06</acronym>
  <official_title>GORE® ENFORM Biomaterial Product Study: A Study to Describe Multi-use Biomaterial Performance in Hernia Patients Undergoing Open Hernia Repair Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>W.L.Gore &amp; Associates</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>W.L.Gore &amp; Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, non-randomized, multicenter study with two independent arms (Ventral /&#xD;
      Incisional Hernia Repair and Diaphragmatic / Hiatal Hernia Repair) wherein the primary&#xD;
      objective of this study is to collect GORE® ENFORM Biomaterial product commercial-use data on&#xD;
      device functional performance in specific treatment populations for regulatory submissions&#xD;
      outside of the United States. The primary objective of this study is to collect GORE® ENFORM&#xD;
      Biomaterial product commercial-use data on device functional performance in specific&#xD;
      treatment populations for regulatory submissions outside of the United States.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2021</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hernia Recurrence - Primary Device Endpoint</measure>
    <time_frame>Through 24 months</time_frame>
    <description>Clinical diagnosed hernia recurrence in the area of the initial hernia repair (within device overlap at time of index procedure).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of SSI - Primary Procedural Endpoint 1</measure>
    <time_frame>1 month follow up</time_frame>
    <description>Incidence of SSI, reported as a composite and individually.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of SSO - Primary Procedural Endpoint 2</measure>
    <time_frame>1 month follow up</time_frame>
    <description>Incidence of SSO, reported as a composite and individually.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from potential device-related SAEs - Secondary endpoint 1</measure>
    <time_frame>Through 24 months</time_frame>
    <description>Freedom from potential device-related Serious Adverse Events will be reported descriptively with no formal goals or hypothesis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-intervention at study-treated location - Secondary Endpoint 2</measure>
    <time_frame>Through 24 months</time_frame>
    <description>Surgical re-intervention in the area of the hernia repaired initially (e.g. drain insertion, infection, surface issues, second operation, etc.) will be reported descriptively with no formal goals or hypothesis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life in Carolinas Comfort Scale - Secondary Endpoint 3</measure>
    <time_frame>Through 24 months</time_frame>
    <description>For ventral hernia subjects; change in Quality of Life in Carolinas Comfort Scale as measured by a change in total score of the Carolinas Comfort Scale Quality of Life questionnaire given at follow-up visits.&#xD;
Minimum Total Score is 0 and maximum Total Score is 115. Lower score means better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relief from GERD Symptoms - Secondary Endpoint 4</measure>
    <time_frame>Through 24 months</time_frame>
    <description>For diaphragmatic hernia subjects; relief from GERD symptoms as measured by a decrease in the total score of the Gastroesophageal Reflux Disease Health Related Quality of Life (GERD-HRQL) questionnaire given at follow-up visits.&#xD;
Total Score: Calculated by summing the individual scores to questions 1-15. Greatest possible score (worst symptoms) = 75 Lowest possible score (no symptoms) = 0&#xD;
Heartburn Score: Calculated by summing the individual scores to questions 1-6. Worst heartburn symptoms = 30 No heartburn symptoms = 0 Scores of ≤ 12 with each individual question not exceeding 2 indicate heartburn elimination.&#xD;
Regurgitation Score: Calculated by summing the individual scores to questions 10-15.&#xD;
Worst regurgitation symptoms = 30 No regurgitation symptoms = 0 Scores of ≤ 12 with each individual question not exceeding 2 indicate regurgitation elimination.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Ventral Hernia</condition>
  <condition>Hernia, Hiatal</condition>
  <condition>Hernia, Diaphragmatic</condition>
  <condition>Hernia Incisional</condition>
  <arm_group>
    <arm_group_label>Ventral/Incisional Hernia - Preperitoneal ENFORM Biomaterial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ventral/Incisional Hernia - Intraperitoneal ENFORM Biomaterial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hiatal/Diaphragmatic Hernia - Preperitoneal ENFORM Biomaterial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hiatal/Diaphragmatic Hernia-Intraperitoneal ENFORM Biomaterial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gore ENFORM Biomaterial (Preperitoneal)</intervention_name>
    <description>ENFORM Biomaterial bioabsorbable hernia mesh</description>
    <arm_group_label>Hiatal/Diaphragmatic Hernia - Preperitoneal ENFORM Biomaterial</arm_group_label>
    <arm_group_label>Ventral/Incisional Hernia - Preperitoneal ENFORM Biomaterial</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Gore ENFORM Biomaterial (Intraperitoneal)</intervention_name>
    <description>ENFORM Biomaterial bioabsorbable hernia mesh</description>
    <arm_group_label>Hiatal/Diaphragmatic Hernia-Intraperitoneal ENFORM Biomaterial</arm_group_label>
    <arm_group_label>Ventral/Incisional Hernia - Intraperitoneal ENFORM Biomaterial</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. At least 18 years old at the time of informed consent. Minimum age required by state&#xD;
             regulations (as applicable).&#xD;
&#xD;
          2. A scored Class I (Clean) using CDC Surgical Wound Classification system (assessed&#xD;
             periprocedure).&#xD;
&#xD;
          3. A planned implant with GORE® ENFORM Biomaterial.&#xD;
&#xD;
          4. A scored Grade 1 or Grade 2 using the Ventral Hernia Working Group Grading system&#xD;
             (assessed periprocedure).&#xD;
&#xD;
          5. Willing to provide informed consent and comply with follow-up requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Treated in another drug or medical device study within 1 year of study enrollment.&#xD;
&#xD;
          2. Implanted with GORE® ENFORM Biomaterial in the repair of cardiovascular defects.&#xD;
&#xD;
          3. Hernia repair will be performed as part of a bridged procedure&#xD;
&#xD;
          4. A BMI &gt;35.&#xD;
&#xD;
          5. Evidence of a systemic infection.&#xD;
&#xD;
          6. Cirrhosis or undergoing dialysis.&#xD;
&#xD;
          7. A wound-healing disorder.&#xD;
&#xD;
          8. Immunocompromised such as, with HIV or transplant, or receiving chemo or radiation&#xD;
             therapy.&#xD;
&#xD;
          9. Expected to undergo mesh implantation in conjunction with any bariatric procedure and&#xD;
             / or panniculectomy procedure.&#xD;
&#xD;
         10. Inability to perform primary closure of crura (hiatal hernia only and assessed&#xD;
             periprocedure).&#xD;
&#xD;
         11. A stoma.&#xD;
&#xD;
         12. Co-morbid conditions that may limit their ability to comply with study and follow-up&#xD;
             requirements&#xD;
&#xD;
         13. Pregnant and / or lactating at time of informed consent signature.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd Heniford, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Atrium Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vanessa Tanner</last_name>
    <phone>800-437-8181</phone>
    <email>ENF1806@wlgore.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrew Garcia</last_name>
    <phone>800-437-8181</phone>
    <email>ENF1806@wlgore.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sarasota Memorial HealthCare System</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamela Fonseca, MSN, RN</last_name>
    </contact>
    <investigator>
      <last_name>Jonathan Yunis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atrium Health</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Heniford, MD</last_name>
    </contact>
    <investigator>
      <last_name>Todd Heniford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 24, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hernia</keyword>
  <keyword>ventral</keyword>
  <keyword>hiatal</keyword>
  <keyword>diaphragmatic</keyword>
  <keyword>incisional</keyword>
  <keyword>mesh</keyword>
  <keyword>Gore</keyword>
  <keyword>W.L. Gore</keyword>
  <keyword>Enform</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Hernia, Ventral</mesh_term>
    <mesh_term>Hernia, Diaphragmatic</mesh_term>
    <mesh_term>Incisional Hernia</mesh_term>
    <mesh_term>Hernia, Hiatal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

